Compare Amgen, Inc. (AMGN) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs MPLX LP — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while MPLX LP trades at $58.43 (market cap $57.79B). The key difference: Amgen, Inc. is far larger — about 3.4× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.56%). Which is the better fit depends on your goals.
| AMGN | MPLX | |
|---|---|---|
Market Cap | $196.12B | $57.79B |
Sector | Health | Technology |
52-Week High | $388.16 | $59.17 |
52-Week Low | $271.18 | $47.80 |
Enterprise Value | $241.41B | $82.42B |
Dividend Yield | 2.77% | 7.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MPLX trades at $56.95, down 0.42% on the day, with a bullish technical outlook supported by moving averages and key support at $56. The company reported strong profitability with a 41.24% net income margin and a trailing P/E of 12.33. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 results pending. A $1.08 dividend for H1-26 underscores its income appeal, while analyst consensus remains strongly positive with a $60.60 price target.
The outlook for MPLX is favorable, driven by stable cash flows from fee-based midstream operations and a high dividend yield. Risks include exposure to energy market volatility and a high debt-to-asset ratio of 90.06%. With 71% of analysts rating it a Buy and solid fundamentals, the stock presents a compelling opportunity for income-focused investors, though macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
